ArticleProbiotics and antimicrobial proteins2026
Dietary Pichia Guilliermondii Improves Intestinal Digestive Capacity and Barrier Integrity in Weaned Piglets Associated with Gut Microbiota-Related Glutathione Metabolism.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Yeast-derived feed additives are increasingly used to support intestinal health after weaning, but dose-response evidence and mechanistic information for inactivated Pichia guilliermondii product (PG) in pigs remain limited. A total of 360 piglets (initial body weight, 6.30 ± 0.06 kg) received diets containing 0, 800, 1600, 2400, or 3200 mg/kg inactivated PG product for 28 days. Under the present experimental conditions, the 800 mg/kg PG group showed the greatest weight gain, final body weight, and nutrient digestibility of dry matter and crude protein among the tested dietary levels (P < 0.05). Accordingly, the control and 800 mg/kg PG (PGO) groups were selected for downstream phenotyping. Compared with controls, PGO group had increased intestinal villus height, digestive enzyme activities, nutrient transporter expression, goblet cell numbers, and tight-junction protein abundance, and reduced serum diamine oxidase activity (P < 0.05). The PGO group also showed higher systemic and intestinal antioxidant-related indices, accompanied by increased expression of SOD1, GPX4, and NRF2 (P < 0.05). Microbiota analysis showed enrichment of potentially beneficial taxa, including Blautia, Prevotellaceae_NK3B31_group, and Prevotella_9. Colonic metabolomics further revealed higher levels of glycine, serine, and L-cysteine, together with increased intestinal activities and gene/protein expression of glutathione-related enzymes/factors, including GCLM, GCLC, and GSS (P < 0.05). These findings indicate that, under the present experimental conditions, 800 mg/kg inactivated PG product was the best-performing tested dose for supporting growth, nutrient utilization, antioxidant-related indices, and intestinal barrier-related indices in weaned piglets, and these responses were associated with changes in gut microbiota-related glutathione metabolism.
Indexed as
Identifiers
42873456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.